Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brexpiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | DRD5 | P21918 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.98 |
| ▸ | HTR1D | P28221 | 1/20 | 0.98 |
| ▸ | HTR1B | P28222 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | HTR1E | P28566 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | GPR183 | P32249 | 1/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brexpiprazole SCHEMBL29445004 | 1.00 | DRD2 (0.98) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL1037592 | 0.99 | DRD2 (1.00) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL29350574 | 0.99 | DRD2 (1.00) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL29870341 | 0.99 | DRD2 (1.00) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL15349907 | 0.98 | DRD2 (0.98) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL14763293 | 0.98 | DRD2 (0.98) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL16583330 | 0.98 | DRD2 (0.98) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL31072680 | 0.98 | DRD2 (0.98) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| Brexpiprazole SCHEMBL29567364 | 0.98 | DRD2 (0.98) | DRD2HTR1AHTR2AADRB2ADRB1 | |
| SCHEMBL1035947 | 0.96 | DRD2 (0.95) | DRD2HTR1AHTR2AADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018087775-A1 | PROCESSES FOR THE PREPARATION OF 7-{4-[4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL]BUTOXY}QUINOLIN-2(1H)-ONE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-17 | — | — | WO | claimed |
| US-20250241909-A1 | INJECTABLE FORMULATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-07-31 | — | — | US | disclosed |
| US-20250121065-A1 | INJECTABLE PREPARATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-17 | — | — | US | disclosed |
| US-20240277702-A1 | INJECTABLE FORMULATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| US-12016927-B2 | Injectable preparation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-25 | — | — | US | disclosed |
| CN-114344259-B | Injectable formulations | 大塚制药株式会社 | 2024-02-13 | — | — | CN | disclosed |
| EP-2841431-B2 | DIHYDRATE OF BENZOTHIOPHENE COMPOUND AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230390399-A1 | INJECTABLE PREPARATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-12-07 | — | — | US | disclosed |
| US-11638757-B2 | Injectable preparation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20230049327-A1 | DIHYDRATE OF BENZOTHIOPHENE COMPOUND OR OF A SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| WO-2013162046-A1 | DIHYDRATE OF BENZOTHIOPHENE COMPOUND OR OF A SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013162048-A1 | INJECTABLE PREPARATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-1869025-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-1869025-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006112464-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016927-B2 | Injectable preparation | TNF, IL1B, F12 | DRD2 782/4885HTR1A 1589/4885HTR2A 2173/4885 |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HTR1A 22/4885HTR2A 29/4885 |
| US-20230390399-A1 | INJECTABLE PREPARATION | TNF, IL1B, F12 | DRD2 782/4885HTR1A 1589/4885HTR2A 2173/4885 |
| US-20250241909-A1 | INJECTABLE FORMULATION | SLC47A1, SLC18A1, ABCB11 | DRD2 2024/4885HTR1A 858/4885HTR2A 707/4885 |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885HTR1A 22/4885HTR2A 29/4885 |
| US-20230049327-A1 | DIHYDRATE OF BENZOTHIOPHENE COMPOUND OR OF A SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | SLC6A3, TPST2, HTT | DRD2 922/4885HTR1A 1150/4885HTR2A 1418/4885 |
| US-20240277702-A1 | INJECTABLE FORMULATION | SLC47A1, SLC18A1, ABCB11 | DRD2 2024/4885HTR1A 858/4885HTR2A 707/4885 |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885HTR1A 22/4885HTR2A 29/4885 |
| US-11638757-B2 | Injectable preparation | TNF, IL1B, F12 | DRD2 785/4885HTR1A 1565/4885HTR2A 2141/4885 |
| US-20250121065-A1 | INJECTABLE PREPARATION | TNF, IL1B, F12 | DRD2 785/4885HTR1A 1565/4885HTR2A 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.